BDSI to discuss planned BEMA Granisetron IND with the FDA

NewsGuard 100/100 Score

BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that the company has been granted a meeting with the U.S. Food and Drug Administration (FDA) to discuss the planned Investigational New Drug (IND) application for BDSI’s antiemetic (anti-nausea and vomiting) product candidate, BEMA Granisetron. The meeting will take place on March 17, 2010. The company will discuss with the FDA clinical development and regulatory plans for BEMA Granisetron, which is anticipated to enter Phase 1 studies in the second quarter of 2010.

“Patients experiencing nausea and vomiting often have difficulty taking oral medications. Additionally, absorption of drug from the gastrointestinal tract can be highly variable in these individuals”

“Patients experiencing nausea and vomiting often have difficulty taking oral medications. Additionally, absorption of drug from the gastrointestinal tract can be highly variable in these individuals,” said Dr. Andrew Finn, Executive Vice President, Product Development at BDSI. “Having a formulation of an antiemetic that does not require swallowing and gastric absorption could possibly lead to faster and more consistent blood levels of drug. We believe that such a product could have significant potential.”

BEMA Granisetron utilizes BDSI’s proprietary BioErodible MucoAdhesive (BEMA) drug delivery technology, which consists of a small, dissolvable, polymer film for application to the buccal mucosa (inner lining of the cheek) to deliver the FDA approved antiemetic drug granisetron (also known as Kytril®, marketed by Genentech). Granisetron is known as a selective 5HT-3 receptor antagonist, which are the most widely used treatments for the prevention of nausea and vomiting related to chemotherapy and radiation. Sales of 5HT-3 antagonists exceeded $1.7 billion in 2008.

Based on the outcome of the discussion with FDA, Phase 3 development could occur as early as the beginning of 2011. BEMA Granisetron would be the third BEMA product to enter clinical development and follows the recent FDA approval of the first product to use the BEMA drug delivery technology, ONSOLIS (fentanyl buccal soluble film), for the treatment of breakthrough pain in opioid tolerant patients with cancer. The company also announced last month positive Phase 2 results for its latest pain product, BEMA Buprenorphine, a potential treatment for acute and chronic pain.

Source:

BioDelivery Sciences International

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Case study: Cannabis might dampen the pain, but amplify the psychosis!